Brain Neoplasms
119
17
20
58
Key Insights
Highlights
Success Rate
77% trial completion
Published Results
17 trials with published results (14%)
Research Maturity
58 completed trials (49% of total)
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 72/100
14.3%
17 terminated out of 119 trials
77.3%
-9.2% vs benchmark
7%
8 trials in Phase 3/4
29%
17 of 58 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 58 completed trials
Clinical Trials (119)
A Study to Learn About the Study Medicine Called PF-07799544 as Monotherapy or in Combination in People With Advanced Solid Tumors
MR Elastography in Intracranial Lesions: Feasibility & Accuracy
Use of Fluorescence in Gliomas
Guided Meditation During Radiation Therapy for Brain Tumors
Ommaya Reservoir Placement at the Time of Biopsy for Longitudinal Biomarker Collection in Patients With Brain Tumors
OT SMILE: Occupational Therapy Group Intervention for Primary Brain Tumour Patients
[18F]FET PET for Characterization of Progressive or Recurrent Glioma From Treatment Related Changes
Study of Abemaciclib and Elacestrant in Participants With Brain Metastasis Due to ER+/HER-2- Breast Cancer
Detection of Brain Metastases Using a Novel Gadolinium-Weighted MRI Sequence: A Prospective Comparison
Platelets Activation in Brain Neoplasms
Phase 2 Ascending Dose Safety and Efficacy Study of RVP-001, a Manganese-based MRI Contrast Agent
DETERMINE Trial Treatment Arm 03: Entrectinib in Adult, Paediatric and Teenage/Young Adult Patients With ROS1 Gene Fusion-Positive Cancers.
HOBSCOTCH-CA (HOme-Based Self-management and COgnitive Training CHanges Lives in Brain CAncer)
Intraoperative Fluorescence-Guided Aspirate Tissue Monitoring of 5-ALA During Brain Tumor Surgery
A FIH Study of PF-07284890 in Participants With BRAF V600 Mutant Solid Tumors With and Without Brain Involvement
Study of [68Ga]-FF58 in Patients With Selected Solid Tumors Expected to Overexpress αvβ3 and αvβ5 Integrins.
Oral Pazopanib Plus Oral Topotecan Metronomic Antiangiogenic Therapy for Recurrent Glioblastoma Multiforme (A) Without Prior Bevacizumab Exposure and (B) After Failing Prior Bevacizumab
Phase I Study of JYP0322 in ROS1 Fusion-Positive Solid Tumors
Physical Activity and Quality of Life in Childhood Cancersurvivors- a Long-term Follow-up
BRAINFUL (BRAIN Tumor Focused Ultrasound-enabled Liquid Biopsy) Trial